Comment on "Ten-year survival outcomes of concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the IMRT era: A retrospective cohort study stratified by high- and low-risk profiles".
作者信息
Topkan Erkan, Somay Efsun, Ozturk Duriye, Selek Ugur
机构信息
Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey.
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Baskent University, Ankara, Turkey.
出版信息
Clin Transl Radiat Oncol. 2025 Jul 29;54:101025. doi: 10.1016/j.ctro.2025.101025. eCollection 2025 Sep.
Abstract
摘要
相似文献
1
Comment on "Ten-year survival outcomes of concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the IMRT era: A retrospective cohort study stratified by high- and low-risk profiles".
Clin Transl Radiat Oncol. 2025 Jul 29;54:101025. doi: 10.1016/j.ctro.2025.101025. eCollection 2025 Sep.
2
Ten-year survival outcomes of concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the IMRT era: A retrospective cohort study stratified by high- and low-risk profiles.
Clin Transl Radiat Oncol. 2025 Jun 27;54:101006. doi: 10.1016/j.ctro.2025.101006. eCollection 2025 Sep.
3
Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
J Cancer Res Clin Oncol. 2019 Jul;145(7):1857-1864. doi: 10.1007/s00432-019-02925-z. Epub 2019 May 6.
4
A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.
Ann Oncol. 2015 Jan;26(1):205-211. doi: 10.1093/annonc/mdu507. Epub 2014 Oct 29.
5
Ten-year outcomes of IMRT with chemotherapy versus IMRT alone for stage II-IVa nasopharyngeal carcinoma: a retrospective study.
Discov Oncol. 2025 Jul 19;16(1):1378. doi: 10.1007/s12672-025-03230-7.
6
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.
JAMA Oncol. 2025 Jun 18. doi: 10.1001/jamaoncol.2025.1597.
7
Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
JAMA Oncol. 2024 Apr 1;10(4):456-463. doi: 10.1001/jamaoncol.2023.6552.
8
Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China.
J Cancer Res Clin Oncol. 2020 Sep;146(9):2369-2378. doi: 10.1007/s00432-020-03229-3. Epub 2020 May 3.
9
Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study.
Cancer Immunol Immunother. 2025 Jun 17;74(8):241. doi: 10.1007/s00262-025-04100-5.
10
The Changing Therapeutic Role of Chemo-radiotherapy for Loco-regionally Advanced Nasopharyngeal Carcinoma from Two/Three-Dimensional Radiotherapy to Intensity-Modulated Radiotherapy: A Network Meta-Analysis.
Theranostics. 2017 Oct 17;7(19):4825-4835. doi: 10.7150/thno.21815. eCollection 2017.
本文引用的文献
1
Ten-year outcomes of IMRT with chemotherapy versus IMRT alone for stage II-IVa nasopharyngeal carcinoma: a retrospective study.
Discov Oncol. 2025 Jul 19;16(1):1378. doi: 10.1007/s12672-025-03230-7.
2
Ten-year survival outcomes of concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the IMRT era: A retrospective cohort study stratified by high- and low-risk profiles.
Clin Transl Radiat Oncol. 2025 Jun 27;54:101006. doi: 10.1016/j.ctro.2025.101006. eCollection 2025 Sep.
3
Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Cancer Res Treat. 2024 Oct;56(4):1058-1067. doi: 10.4143/crt.2023.1343. Epub 2024 Feb 19.
4
Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial.
Int J Radiat Oncol Biol Phys. 2023 Nov 15;117(4):914-924. doi: 10.1016/j.ijrobp.2023.06.001. Epub 2023 Jun 24.
5
Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis.
Lancet Oncol. 2023 Jun;24(6):611-623. doi: 10.1016/S1470-2045(23)00163-8.
6
Efficacy and Safety of Concurrent Chemoradiotherapy Combined With Induction Chemotherapy or Adjuvant Chemotherapy in Patients With Stage II-IVA Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis and Meta-Analysis.
Front Oncol. 2021 Dec 3;11:778836. doi: 10.3389/fonc.2021.778836. eCollection 2021.
7
Clinical endpoints in oncology - a primer.
Am J Cancer Res. 2021 Apr 15;11(4):1121-1131. eCollection 2021.
8
Censoring in clinical trials: review of survival analysis techniques.
Indian J Community Med. 2010 Apr;35(2):217-21. doi: 10.4103/0970-0218.66859.
Zotero 插件